StreetInsider.com News Articles

Baird Medical says no known reason for recent share price drop

Wed, 04 Nov 2026 16:02:29 -0500

Baird Medical Investment Holdings Limited (NASDAQ: BDMD) said it is not aware of any material development or undisclosed reason that would explain a recent decline in its ordinary share price.

The company, which specializes in microwave ablation (MWA) medical devices, issued a statement saying it is monitoring fluctuations in its share price and associated trading activity.

Baird Medical management stated that the company's current market valuation does not accurately reflect its underlying business fundamentals or growth potential, according to the press release.

Baird Medical says no known reason for recent share price drop

Wed, 04 Nov 2026 16:02:29 -0500

Baird Medical Investment Holdings Limited (NASDAQ: BDMD) said it is not aware of any material development or undisclosed reason that would explain a recent decline in its ordinary share price.

The company, which specializes in microwave ablation (MWA) medical devices, issued a statement saying it is monitoring fluctuations in its share price and associated trading activity.

Baird Medical management stated that the company's current market valuation does not accurately reflect its underlying business fundamentals or growth potential, according to the press release.

Baird Medical Issues Statement Regarding Recent Share Price Volatility

Wed, 04 Nov 2026 16:02:00 -0500

NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Limited (NASDAQ: BDMD) (“Baird Medical” or the “Company”), a healthcare innovator dedicated to microwave ablation (MWA) technology, has provided the following statement regarding recent volatility in the market price of its ordinary shares.

The Company is closely monitoring these fluctuations in the market price of its ordinary shares and the associated trading activity, and is not currently aware of any material development or otherwise undisclosed reason that would explain the recent decline in its ordinary share price.

Baird Medical management believes that the Company’s

Baird Medical Issues Statement Regarding Recent Share Price Volatility

Wed, 04 Nov 2026 16:02:00 -0500

NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Limited (NASDAQ: BDMD) (“Baird Medical” or the “Company”), a healthcare innovator dedicated to microwave ablation (MWA) technology, has provided the following statement regarding recent volatility in the market price of its ordinary shares.

Baird Medical management believes that the Company’s

Baird Medical receives Nasdaq minimum bid price deficiency notice

Wed, 04 Nov 2026 16:01:24 -0500

Baird Medical Investment Holdings Limited (NASDAQ: BDMD) disclosed that it received a notification letter from Nasdaq dated November 2, 2026, stating the company is not in compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).

The rule requires listed securities to maintain a minimum closing bid price of $1.00 per share for continued listing on the Nasdaq Capital Market. A deficiency is triggered when the bid price falls below that threshold for 30 consecutive business days.

The notification does not result in an immediate delisting. Baird Medical's shares will continue to trade on the Nasdaq Capital Market under the

Baird Medical Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

Wed, 04 Nov 2026 16:01:00 -0500

NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Limited (NASDAQ: BDMD) (“Baird Medical” or the “Company”), a healthcare innovator dedicated to microwave ablation (MWA) technology, today announced that the Company received a notification letter (the “Notification Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), dated November 2, 2026, notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. This notification does not result in the delisting of the Company’s

Baird Medical Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

Wed, 04 Nov 2026 16:01:00 -0500

NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Limited (NASDAQ: BDMD) (“Baird Medical” or the “Company”), a healthcare innovator dedicated to microwave ablation (MWA) technology, today announced that the Company received a notification letter (the “Notification Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), dated November 2, 2026, notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. This notification does not result in the delisting of the Company’s

Baird Medical signs China distribution deal worth RMB 6M initially

Mon, 02 Nov 2026 08:05:02 -0500

Baird Medical Investment Holdings Limited (NASDAQ: BDMD) announced that its China subsidiary, Nanjing Changcheng Medical Equipment Company Limited, has entered into an exclusive distribution agreement with China Resources Pharmaceutical Commercial Group Medical Devices Co., Ltd., a subsidiary of China Resources Pharmaceutical Group Limited (Stock Code: 03320.HK).

Under the agreement, China Resources Medical Devices will serve as the exclusive distributor for Baird Medical's microwave ablation (MWA) products across 19 markets in China, with a focus on regions where Baird Medical has had limited direct commercial presence. Upon signing, China Resources Medical Devices placed an initial purchase order of approximately RMB 6 million

Baird Medical signs China distribution deal worth RMB 6M initially

Mon, 02 Nov 2026 08:05:02 -0500

Baird Medical and China Resources Pharmaceutical Commercial Group Medical Devices Sign Strategic Distribution Agreement to Expand Access to Microwave Ablation in China

Mon, 02 Nov 2026 08:00:00 -0500

China Resources Medical Devices to serve as exclusive distributor for Baird’s microwave ablation (MWA) products in 19 markets in the PRC

Agreement includes initial purchase order of RMB 6 million ($900,000)

NEW YORK, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Limited (NASDAQ: BDMD) (“Baird Medical” or the “Company”), a global leader in microwave ablation (MWA) technology, today announced that its PRC subsidiary, Nanjing Changcheng Medical Equipment Company Limited, has entered into a distribution agreement with China Resources Pharmaceutical Commercial Group Medical Devices Co., Ltd. (“China Resources Medical Devices”), a

Baird Medical and China Resources Pharmaceutical Commercial Group Medical Devices Sign Strategic Distribution Agreement to Expand Access to Microwave Ablation in China

Mon, 02 Nov 2026 08:00:00 -0500

China Resources Medical Devices to serve as exclusive distributor for Baird’s microwave ablation (MWA) products in 19 markets in the PRC

Agreement includes initial purchase order of RMB 6 million ($900,000)

Baird Medical gets device approvals in Vietnam and Egypt

Mon, 19 Oct 2026 08:03:09 -0500

Baird Medical Investment Holdings Limited (NASDAQ: BDMD) announced medical device registrations in Vietnam and preliminary regulatory approval in Egypt for its microwave ablation technology, according to a company press release dated Oct. 19, 2026.

In Vietnam, the company received Class C medical device registration certificates for several products, including its J-series microwave ablation needles for benign thyroid nodules, G-series needles for liver tumors, and MTI-5AT and MTI-5ET microwave ablation generators. The certificates follow an initial product registration issued in January 2026.

In Egypt, the Egyptian Drug Authority granted preliminary approval in January 2026 for Baird Medical's BD-GT Microwave Ablation System and related

Baird Medical gets device approvals in Vietnam and Egypt

Mon, 19 Oct 2026 08:03:09 -0500

In Egypt, the Egyptian Drug Authority granted preliminary approval in January 2026 for Baird Medical's BD-GT Microwave Ablation System and related

Baird Medical Announces Regulatory Milestones in Vietnam and Egypt, Expanding International Reach of Microwave Ablation Technology

Mon, 19 Oct 2026 08:00:00 -0500

Company Continues to Advance Global Regulatory Strategy While Supporting U.S. Commercial Expansion

NEW YORK, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Limited (NASDAQ: BDMD) (“Baird Medical” or the “Company”), a global leader in microwave ablation (MWA) technology, today announced additional medical device registrations in Vietnam and preliminary regulatory approval in Egypt. The preliminary approval in Egypt will help the Company bring its technology to one of the largest markets in the Middle East, while the product registrations in Vietnam will enable Baird to expand the addressable patient population in this key Southeast Asian country. These milestones

Baird Medical Announces Regulatory Milestones in Vietnam and Egypt, Expanding International Reach of Microwave Ablation Technology

Mon, 19 Oct 2026 08:00:00 -0500

Company Continues to Advance Global Regulatory Strategy While Supporting U.S. Commercial Expansion

Baird Medical Highlights Global Expansion and Strategic Progress During Third Quarter 2026

Mon, 05 Oct 2026 08:00:00 -0500

Quarter included presentation at H.C. Wainwright Global Investment Conference, strategic partnership with Alpmed, new regulatory registrations, and continued physician training

NEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Ltd. (“Baird Medical” or the “Company”) (NASDAQ: BDMD), a medical device company focused on the development and commercialization of minimally invasive treatment technologies, today highlighted key business and operational developments from the third quarter of 2026, including expansion into new international markets, continued physician training initiatives and the addition of irreversible electroporation (IRE) technology to its broader technology portfolio through a strategic partnership.

“During the third quarter,

Baird Medical Highlights Global Expansion and Strategic Progress During Third Quarter 2026

Mon, 05 Oct 2026 08:00:00 -0500

Quarter included presentation at H.C. Wainwright Global Investment Conference, strategic partnership with Alpmed, new regulatory registrations, and continued physician training

“During the third quarter,

Form SCHEDULE 13G Baird Medical Investment Filed by: L1 Capital Global Opportunities Master Fund, Ltd.

Thu, 01 Oct 2026 16:10:00 -0500

si-local-file:///var/storage/secattach/20261001/27136013.html

Form 6-K Baird Medical Investment For: Sep 30

Wed, 30 Sep 2026 16:05:00 -0500

si-local-file:///var/storage/secattach/20260930/27128663.html

Form 6-K Baird Medical Investment For: Jun 30

Wed, 30 Sep 2026 07:19:00 -0500

si-local-file:///var/storage/secattach/20260930/27125222.html

Form 424B5 Baird Medical Investment

Thu, 24 Sep 2026 16:05:00 -0500

si-local-file:///var/storage/secattach/20260924/27102219.html

Baird Medical to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Tue, 15 Sep 2026 08:00:00 -0500

NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Limited (“Baird Medical” or the “Company”) (Nasdaq: BDMD), a global medical technology company focused on the development and commercialization of minimally invasive treatment solutions, today announced that management will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York City.

H.C. Wainwright 28th Annual Global Investment Conference
Date: Wednesday, September 16, 2026
Time: 11:30 a.m. ET
Location: Lotte New York Palace Hotel, New York City

A live webcast of the presentation will be available through the Investor Relations section of

Baird Medical to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Tue, 15 Sep 2026 08:00:00 -0500

H.C. Wainwright 28th Annual Global Investment Conference
Date: Wednesday, September 16, 2026
Time: 11:30 a.m. ET
Location: Lotte New York Palace Hotel, New York City

A live webcast of the presentation will be available through the Investor Relations section of

Baird Medical Highlights Participation at CIRSE 2026 and Showcases Microwave Ablation Technology

Mon, 14 Sep 2026 08:00:00 -0500

Company Engaged with Interventional Radiology Community at Leading Global Congress in Copenhagen

COPENHAGEN, Denmark, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Ltd. (“Baird Medical” or the “Company”) (Nasdaq: BDMD), a global medical technology company focused on the development and commercialization of minimally invasive treatment solutions, today highlighted its participation at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2026 Annual Congress, held at the Bella Center Copenhagen.

Throughout the congress, Baird Medical showcased its Microwave Ablation (MWA)

Baird Medical Highlights Participation at CIRSE 2026 and Showcases Microwave Ablation Technology

Mon, 14 Sep 2026 08:00:00 -0500

Company Engaged with Interventional Radiology Community at Leading Global Congress in Copenhagen

Throughout the congress, Baird Medical showcased its Microwave Ablation (MWA)